Topics

AstraZeneca's roxadustat boosts haemoglobin levels in two Phase 3 trials

06:14 EST 8 Nov 2019 | Pharmafile

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) levels in non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients with anaemia as a result of chronic kidney disease after meeting its primary endpoint in two separate clinical trials.

In the first, the OLYMPUS trial, AZ’s drug was shown to increase hB levels from baseline by a mean 1.75g/dL averaged over weeks 28 to 52, compared to 0.40g/dL with placebo.

read more

Original Article: AstraZeneca's roxadustat boosts haemoglobin levels in two Phase 3 trials

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's roxadustat boosts haemoglobin levels in two Phase 3 trials"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...